Thymosin Beta-4
Also called Tβ4, RGN-352
Research reference
- Research amount range
- 42–1260 mg per administration — not a starting amount
- Reference frequency
- Every day — catalogue input, not a personal schedule
- Evidence route
- Intravenous in the cited evidence; formulation matters.
- Model accumulation timescale
- ~12.5 days — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
Thymosin Beta-4
Evidence gap- When change was measured
- Human exposure or dose research exists for Thymosin Beta-4, but this catalogue has no source-backed window for a visible or functional result. Pharmacokinetic or biomarker timing is not the same as outcome timing.
- When to assess
- No evidence-based reassessment point is available for this catalogue entry. Half-life or clearance time cannot be used as a proxy for when a result should appear.
- Conditions and limitations
- No source-backed special condition—such as fasting, local injection, exercise timing, or a companion compound—has been established for the claimed outcomes. Route and formulation still matter.
- When to stop
- No validated target, maintenance phase, or quit rule is available. Do not extend or increase exposure solely because an expected result has not appeared; a severe or persistent reaction warrants stopping and prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Thymosin β4 estimates vary widely; the TB-500 fragment page carries the same rough figure. Read as order-of-magnitude.
The full protein, distinct from the TB-500 fragment sold under that name. Human evidence is an intravenous safety study, so no subcutaneous schedule is established and no schedule table is shown; figures do not transfer to the fragment. The intravenous amounts studied (42–1260 mg) were infusions, not a vialled product, so the vial size shown is nominal — set just above the smallest studied amount so the calculator shows a possible single-vial draw rather than an impossible one.
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 4.13× single dose
- Time to steady state
- 12.5days
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Ruff D et al., Ann N Y Acad Sci 2010;1194:223First-in-human intravenous thymosin β4 (RGN-352), single and 14-day daily doses across four ascending cohorts of 42, 140, 420 and 1260 mg, was assessed for safety in volunteers; no subcutaneous schedule was fixed.
- Thymosin β4 preclinical repair literatureThe full protein's human data is limited to intravenous safety work; it is the parent molecule of the TB-500 fragment, and figures do not carry between the two.